Robert H. Pierce
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Robert H. Pierce has a total of 588 co-authors. Here are the top co-authors by number of shared publications:
- Jean S. Campbell
Department of Surgery, and
22 shared publications - Cecilia Ching Sze Yeung
Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA
21 shared publications - Kimberly S. Smythe
Fred Hutchinson Cancer Center 7 Translational Science and Therapeutics Division Seattle, Washington
19 shared publications - Adil Daud
Department of Medicine University of California San Francisco California USA
17 shared publications Christopher G. Twitty
12 shared publications- Robin Lewis Jones
Sarcoma Unit, Royal Marsden NHS Foundation Trust, London, UK
12 shared publications
Latest Publications
- Open Access
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Phase I Study of ROR1-Specific CAR-T Cells in Advanced Hematopoietic and Epithelial Malignancies
Supplementary Table 3: Summary of adverse events Cohorts A and B, NCI CTCAE grading.
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Phase I Study of ROR1-Specific CAR-T Cells in Advanced Hematopoietic and Epithelial Malignancies
Supplementary Table 3: Summary of adverse events Cohorts A and B, NCI CTCAE grading.
- Open Access
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Phase I Study of ROR1-Specific CAR-T Cells in Advanced Hematopoietic and Epithelial Malignancies
Supplementary Figure 2: Toxicity Assessment.
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Phase I Study of ROR1-Specific CAR-T Cells in Advanced Hematopoietic and Epithelial Malignancies
Supplementary Figure 2: Toxicity Assessment.
- Open Access
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Phase I Study of ROR1-Specific CAR-T Cells in Advanced Hematopoietic and Epithelial Malignancies
Supplementary Figure 3: Lymphodepletion and CAR T cell expansion.
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Phase I Study of ROR1-Specific CAR-T Cells in Advanced Hematopoietic and Epithelial Malignancies
Supplementary Figure 3: Lymphodepletion and CAR T cell expansion.
- Open Access
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Phase I Study of ROR1-Specific CAR-T Cells in Advanced Hematopoietic and Epithelial Malignancies
Supplementary Table 2: Patient and tumor characteristics.
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Phase I Study of ROR1-Specific CAR-T Cells in Advanced Hematopoietic and Epithelial Malignancies
Supplementary Table 2: Patient and tumor characteristics.
- Open Access
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Phase I Study of ROR1-Specific CAR-T Cells in Advanced Hematopoietic and Epithelial Malignancies
Supplementary Table 1: Representativeness of Study Participants.
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Phase I Study of ROR1-Specific CAR-T Cells in Advanced Hematopoietic and Epithelial Malignancies
Supplementary Table 1: Representativeness of Study Participants.
- Open Access
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Phase I Study of ROR1-Specific CAR-T Cells in Advanced Hematopoietic and Epithelial Malignancies
Supplementary Figure 1: Strobe Flow Diagram.
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Phase I Study of ROR1-Specific CAR-T Cells in Advanced Hematopoietic and Epithelial Malignancies
Supplementary Figure 1: Strobe Flow Diagram.
- Open Access
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data 1 from Phase I Study of ROR1-Specific CAR-T Cells in Advanced Hematopoietic and Epithelial Malignancies
Supplementary Data 1: Study Protocol.
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 1 from Phase I Study of ROR1-Specific CAR-T Cells in Advanced Hematopoietic and Epithelial Malignancies
Supplementary Data 1: Study Protocol.
- Open Access
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Phase I Study of ROR1-Specific CAR-T Cells in Advanced Hematopoietic and Epithelial Malignancies
Supplementary Figure 4: Flow cytometric analysis of T cell phenotypes in apheresis, infusion products and EGFRt + CAR T cells at peak of expansion.
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Phase I Study of ROR1-Specific CAR-T Cells in Advanced Hematopoietic and Epithelial Malignancies
Supplementary Figure 4: Flow cytometric analysis of T cell phenotypes in apheresis, infusion products and EGFRt + CAR T cells at peak of expansion.
- Open Access
- 28 October 2024
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (3) , 503-514
Phase I Study of ROR1-Specific CAR-T Cells in Advanced Hematopoietic and Epithelial Malignancies
Purpose: The receptor tyrosine kinase–like orphan receptor 1 (ROR1) is expressed in hematopoietic and epithelial cancers but has limited expression on normal adult tissues. This phase I study evaluated the safety of targeting ROR1 with autologous T lymphocytes engineered to express a ROR1 chimeric antigen receptor (CAR). Secondary objectives evaluated the persistence, trafficking, and antitumor activity of CAR-T cells. Patients and Methods: Twenty-one patients with ROR1+ tumors received CAR-T cells at one of four dose levels: 3.3 × 105, 1 × 106, 3.3 × 106, and 1 × 107 cells/kg body weight, administered after lymphodepletion with cyclophosphamide/fludarabine or oxaliplatin/cyclophosphamide. Cohort A included patients with chronic lymphocytic leukemia (CLL, n = 3); cohort B included patients with triple-negative breast cancer (TNBC, n = 10) or non–small cell lung cancer (NSCLC, n = 8). A second infusion was administered to one patient in cohort A with residual CLL in the marrow and three patients in cohort B with stable disease after first infusion. Results: Treatment was well tolerated, apart from one dose-limiting toxicity at dose level 4 in a patient with advanced NSCLC. Two of the three (67%) patients with CLL showed robust CAR-T–cell expansion and a rapid antitumor response. In patients with NSCLC and TNBC, CAR-T cells expanded to variable levels and infiltrated tumors poorly and 1 of 18 patients (5.5%) achieved partial response by RECIST 1.1. Conclusions: ROR1 CAR-T cells were well tolerated in most patients. Antitumor activity was observed in CLL but was limited in TNBC and NSCLC. Immunogenicity of the CAR and lack of sustained tumor infiltration were identified as limitations. See related commentary by Kobold, p. 437
- 28 October 2024
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (3) , 503-514
Open AccessPhase I Study of ROR1-Specific CAR-T Cells in Advanced Hematopoietic and Epithelial Malignancies
Purpose: The receptor tyrosine kinase–like orphan receptor 1 (ROR1) is expressed in hematopoietic and epithelial cancers but has limited expression on normal adult tissues. This phase I study evaluated the safety of targeting ROR1 with autologous T lymphocytes engineered to express a ROR1 chimeric antigen receptor (CAR). Secondary objectives evaluated the persistence, trafficking, and antitumor activity of CAR-T cells. Patients and Methods: Twenty-one patients with ROR1+ tumors received CAR-T cells at one of four dose levels: 3.3 × 105, 1 × 106, 3.3 × 106, and 1 × 107 cells/kg body weight, administered after lymphodepletion with cyclophosphamide/fludarabine or oxaliplatin/cyclophosphamide. Cohort A included patients with chronic lymphocytic leukemia (CLL, n = 3); cohort B included patients with triple-negative breast cancer (TNBC, n = 10) or non–small cell lung cancer (NSCLC, n = 8). A second infusion was administered to one patient in cohort A with residual CLL in the marrow and three patients in cohort B with stable disease after first infusion. Results: Treatment was well tolerated, apart from one dose-limiting toxicity at dose level 4 in a patient with advanced NSCLC. Two of the three (67%) patients with CLL showed robust CAR-T–cell expansion and a rapid antitumor response. In patients with NSCLC and TNBC, CAR-T cells expanded to variable levels and infiltrated tumors poorly and 1 of 18 patients (5.5%) achieved partial response by RECIST 1.1. Conclusions: ROR1 CAR-T cells were well tolerated in most patients. Antitumor activity was observed in CLL but was limited in TNBC and NSCLC. Immunogenicity of the CAR and lack of sustained tumor infiltration were identified as limitations. See related commentary by Kobold, p. 437
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Systemic Interferon-γ Increases MHC Class I Expression and T-cell Infiltration in Cold Tumors: Results of a Phase 0 Clinical Trial
Supplementary Tables 1-3 and Supplementary Tables 1-6
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Systemic Interferon-γ Increases MHC Class I Expression and T-cell Infiltration in Cold Tumors: Results of a Phase 0 Clinical Trial
Supplementary Tables 1-3 and Supplementary Tables 1-6